These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2549606)

  • 21. [Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
    Tani M; Maebashi K; Araake M; Watabe H
    Jpn J Antibiot; 2002 Dec; 55(6):882-5. PubMed ID: 12621742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mode of action of fluoroquinolones.
    Hooper DC
    Drugs; 1999; 58 Suppl 2():6-10. PubMed ID: 10553698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man.
    Wijnands GJ; Cornel JH; Martea M; Vree TB
    Chest; 1990 Dec; 98(6):1440-4. PubMed ID: 2245687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 4-Quinolone interactions with gyrase subunit B inhibitors.
    Lewin CS; Howard BM; Smith JT
    J Med Microbiol; 1991 Dec; 35(6):358-62. PubMed ID: 1661337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
    Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase.
    Hilliard JJ; Krause HM; Bernstein JI; Fernandez JA; Nguyen V; Ohemeng KA; Barrett JF
    Adv Exp Med Biol; 1995; 390():59-69. PubMed ID: 8718602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview of drug interactions with the quinolones.
    Davey PG
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():97-107. PubMed ID: 3053579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
    Onodera Y; Uchida Y; Tanaka M; Sato K
    J Antimicrob Chemother; 1999 Oct; 44(4):533-6. PubMed ID: 10588315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory activity on DNA gyrase and intracellular accumulation of quinolones: structure-activity relationship of Q-35 analogs.
    Ito T; Kojima K; Koizumi K; Nagano H; Nishino T
    Biol Pharm Bull; 1994 Jul; 17(7):927-30. PubMed ID: 8000379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of different classes of inhibitors on DNA gyrase from Mycobacterium smegmatis.
    Chatterji M; Unniraman S; Mahadevan S; Nagaraja V
    J Antimicrob Chemother; 2001 Oct; 48(4):479-85. PubMed ID: 11581225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical utility of DNA gyrase inhibitors.
    Neu HC
    Pharmacol Ther; 1989; 41(1-2):207-21. PubMed ID: 2540495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism and the fluoroquinolones.
    Outman WR; Nightingale CH
    Am J Med; 1989 Dec; 87(6C):37S-42S. PubMed ID: 2690618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereo (C7)-dependent topoisomerase II inhibition and tumor growth suppression by a new quinolone, BO-2367.
    Yoshinari T; Mano E; Arakawa H; Kurama M; Iguchi T; Nakagawa S; Tanaka N; Okura A
    Jpn J Cancer Res; 1993 Jul; 84(7):800-6. PubMed ID: 8396568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vitro and in vivo antibacterial activities of a new quinolone derivative, FD501].
    Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
    Jpn J Antibiot; 1996 Mar; 49(3):264-72. PubMed ID: 8935122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinolones in the aged.
    Nicolle LE
    Drugs; 1999; 58 Suppl 2():49-51. PubMed ID: 10553705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Enoxacin--comparative pharmacokinetics and tissue penetration].
    Sörgel F; Naber KG; Metz R; Morgenroth A
    Infection; 1989; 17 Suppl 1():S14-8. PubMed ID: 2680989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory effects of quinolones on murine hematopoietic progenitor cells and eukaryotic topoisomerase II.
    Akahane K; Hoshino K; Sato K; Kimura Y; Une T; Osada Y
    Chemotherapy; 1991; 37(3):224-6. PubMed ID: 1653684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
    Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
    Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quinolone-resistant mutations of DNA gyrase increase sensitivity to acriflavine.
    Funatsuki K; Tanaka R; Inagaki S; Konno H; Katoh K; Nakamura H
    Biol Pharm Bull; 1998 Jul; 21(7):667-72. PubMed ID: 9703246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mechanisms of bacterial resistance to quinolones].
    Taléns-Visconti R; Garrigues TM; Cantón E
    Rev Esp Quimioter; 2002 Mar; 15(1):25-31. PubMed ID: 12582434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.